U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H15F3N4O3
Molecular Weight 416.3533
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TROVAFLOXACIN

SMILES

[H][C@@]12CN(C[C@]1([H])[C@H]2N)C3=NC4=C(C=C3F)C(=O)C(=CN4C5=CC=C(F)C=C5F)C(O)=O

InChI

InChIKey=WVPSKSLAZQPAKQ-CDMJZVDBSA-N
InChI=1S/C20H15F3N4O3/c21-8-1-2-15(13(22)3-8)27-7-12(20(29)30)17(28)9-4-14(23)19(25-18(9)27)26-5-10-11(6-26)16(10)24/h1-4,7,10-11,16H,5-6,24H2,(H,29,30)/t10-,11+,16+

HIDE SMILES / InChI

Molecular Formula C20H15F3N4O3
Molecular Weight 416.3533
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/trovan.html

Alatrofloxacin is a fluoroquinolone antibiotic developed as a mesylate salt and was sold under brand name Trovan, but was withdrawn from the U.S. market in 2001. Trovan was indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. After intravenous administration, alatrofloxacin is rapidly converted to trovafloxacin, which is responsible for therapeutic effect. Plasma concentrations of alatrofloxacin are below quantifiable levels within 5 to 10 minutes of completion of a 1 hour infusion.

Originator

Curator's Comment: # Pfizer

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
TROVAN PRESERVATIVE FREE

Approved Use

Trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis.

Launch Date

1997
Curative
TROVAN

Approved Use

Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis.

Launch Date

1997
Curative
TROVAN

Approved Use

Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis.

Launch Date

1997
Curative
TROVAN

Approved Use

Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis.

Launch Date

1997
Curative
TROVAN PRESERVATIVE FREE

Approved Use

Trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis.

Launch Date

1997
Curative
TROVAN PRESERVATIVE FREE

Approved Use

Trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis.

Launch Date

1997
Curative
TROVAN PRESERVATIVE FREE

Approved Use

Trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis.

Launch Date

1997
Curative
TROVAN PRESERVATIVE FREE

Approved Use

Trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis.

Launch Date

1997
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.1 mg/L
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TROVAFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.9 mg/L
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TROVAFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
3.3 mg/L
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TROVAFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1 mg/L
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TROVAFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.9 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TROVAFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
11.8 mg × h/L
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TROVAFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
26.2 mg × h/L
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TROVAFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
34.6 mg × h/L
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TROVAFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9.4 mg × h/L
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TROVAFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
32.2 μg × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TROVAFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.5 h
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TROVAFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
10.5 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TROVAFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
12.2 h
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TROVAFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9.2 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TROVAFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
13.6 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TROVAFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
22%
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TROVAFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
25.6%
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TROVAFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
28.3%
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TROVAFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
20.3%
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TROVAFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1000 mg single, oral
Highest studied dose
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
healthy, 27 years
n = 4
Health Status: healthy
Age Group: 27 years
Sex: M
Population Size: 4
Sources:
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (4 patients)
Vomiting (1 patient)
Lightheadedness (4 patients)
Sources:
200 mg 1 times / day steady, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 881
Health Status: unhealthy
Condition: chronic bronchitis or pneumonia
Age Group: adult
Sex: M+F
Population Size: 881
Sources:
Disc. AE: Gastrointestinal disorder NOS, CNS disorder (NOS)...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder NOS (11 patient)
CNS disorder (NOS) (4 patients)
Dizziness (2 patients)
Dermatitis (2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Vomiting 1 patient
1000 mg single, oral
Highest studied dose
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
healthy, 27 years
n = 4
Health Status: healthy
Age Group: 27 years
Sex: M
Population Size: 4
Sources:
Lightheadedness 4 patients
1000 mg single, oral
Highest studied dose
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
healthy, 27 years
n = 4
Health Status: healthy
Age Group: 27 years
Sex: M
Population Size: 4
Sources:
Nausea 4 patients
1000 mg single, oral
Highest studied dose
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
healthy, 27 years
n = 4
Health Status: healthy
Age Group: 27 years
Sex: M
Population Size: 4
Sources:
Gastrointestinal disorder NOS 11 patient
Disc. AE
200 mg 1 times / day steady, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 881
Health Status: unhealthy
Condition: chronic bronchitis or pneumonia
Age Group: adult
Sex: M+F
Population Size: 881
Sources:
Dermatitis 2 patients
Disc. AE
200 mg 1 times / day steady, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 881
Health Status: unhealthy
Condition: chronic bronchitis or pneumonia
Age Group: adult
Sex: M+F
Population Size: 881
Sources:
Dizziness 2 patients
Disc. AE
200 mg 1 times / day steady, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 881
Health Status: unhealthy
Condition: chronic bronchitis or pneumonia
Age Group: adult
Sex: M+F
Population Size: 881
Sources:
CNS disorder (NOS) 4 patients
Disc. AE
200 mg 1 times / day steady, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 881
Health Status: unhealthy
Condition: chronic bronchitis or pneumonia
Age Group: adult
Sex: M+F
Population Size: 881
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim
PubMed

PubMed

TitleDatePubMed
In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells.
2001
Latest industry information on the safety profile of levofloxacin in Japan.
2001
Comparison of side effects of levofloxacin versus other fluoroquinolones.
2001
Telithromycin.
2001
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
2001 Apr
In vitro activity of gemifloxacin (SB-265805) compared to eleven other antimicrobial agents against streptococcal isolates, excluding Streptococcus pneumoniae.
2001 Apr
Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships.
2001 Aug
[In vitro activity of six fluoroquinolones and penicillin against 101 viridans group streptococci characterized by their susceptibility to erythromycin].
2001 Dec
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].
2001 Dec
Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.
2001 Dec
Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci.
2001 Dec
Quinolones and false-positive urine screening for opiates by immunoassay technology.
2001 Dec 26
Guidelines and critical pathways for severe hospital-acquired pneumonia.
2001 Feb
In vitro activity of new quinolones against Clostridium difficile.
2001 Feb
Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila.
2001 Feb
Trovafloxacin-associated leukopenia.
2001 Jan
Multifocal Staphylococcus aureus infection originating from the sacroiliac joint in a patient with rheumatoid arthritis.
2001 Jan
Antibiotic side effects.
2001 Jan
Nigerian government investigates Pfizer drug trial allegations.
2001 Jan 13
Pfizer accused of testing new drug without ethical approval.
2001 Jan 27
Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.
2001 Jul
Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.
2001 Jul
Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents.
2001 Jul
Antimicrobial susceptibility patterns of enterococci in intensive care units in Sweden evaluated by different MIC breakpoint systems.
2001 Jul
Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae.
2001 Jul
Use of broad spectrum antibiotics in six non-university Swiss hospitals.
2001 Jul 28
[Are the antimicrobials used in community-acquired respiratory infection useful for preventing transmission of meningococcal disease? In vitro study].
2001 Jun
Effects of low levels of ciprofloxacin on a chemostat model of the human colonic microflora.
2001 Jun
Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
2001 Jun
Effects of fluoroquinolones on the locomotor activity in rats.
2001 Mar
Comparative in-vitro activity of trovafloxacin and other related drugs against isolates of streptococcus oralis.
2001 Mar
Adverse reactions to fluoroquinolones. an overview on mechanistic aspects.
2001 Mar
Comparative study of treatment with penicillin, ceftriaxone, trovafloxacin, quinupristin-dalfopristin and vancomycin in experimental endocarditis due to penicillin- and ceftriaxone-resistant Streptococcus pneumoniae.
2001 May
Serious liver injury. Leading reason for drug removals, restrictions.
2001 May-Jun
In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens.
2001 May-Jun
A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia.
2001 Nov
Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
2001 Oct
High rates of multiple antibiotic resistance in Streptococcus pneumoniae from healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission.
2001 Oct
Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia.
2001 Oct
Frequency of selection of fluoroquinolone-resistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones.
2001 Oct
Future of the quinolones.
2001 Sep
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
2001 Sep
Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.
2001 Sep 15
In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations.
2001 Sep-Oct
In vitro activity of novel fluoroquinolones against Streptococcus pneumoniae isolated from children with acute otitis media.
2001 Sep-Oct
A critical review of the fluoroquinolones: focus on respiratory infections.
2002
Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.
2002 Feb
In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine.
2002 Feb
Bactericidal mechanism of gatifloxacin compared with other quinolones.
2002 Jan
Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates.
2002 Mar
Patents

Sample Use Guides

In Vivo Use Guide
Nosocomial Pneumonia - 300 mg I.V. followed by 200 mg oral, 10–14 days Community Acquired Pneumonia - 200 mg oral or 200 mg I.V. followed by 200 mg oral, 7–14 days Gynecologic and Pelvic Infections - 300 mg I.V. followed by 200 mg oral, 7–14 days
Route of Administration: Other
Trovafloxacin inhibited Escherichia coli growth with MIC50 = 0.125mg/L
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:21:43 GMT 2023
Edited
by admin
on Fri Dec 15 16:21:43 GMT 2023
Record UNII
9F388J00UK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TROVAFLOXACIN
EMA EPAR   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
7-((1R,5S,6S)-6-AMINO-3-AZABICYCLO(3.1.0)HEX-3-YL)-1-(2,4-DIFLUOROPHENYL)-6-FLUORO-1,4-DIHYDRO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID
Common Name English
TROVAFLOXACIN [MI]
Common Name English
TROVAFLOXACIN [EMA EPAR]
Common Name English
1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, 7-(6-AMINO-3-AZABICYCLO(3.1.0)HEX-3-YL)-1-(2,4-DIFLUOROPHENYL)-6-FLUORO-1,4-DIHYDRO-4-OXO-(1.ALPHA.,5.ALPHA.,6.ALPHA.)-
Common Name English
CP-99219
Code English
trovafloxacin [INN]
Common Name English
TROVAFLOXACIN [VANDF]
Common Name English
Trovafloxacin [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-ATC J01MA13
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
WHO-VATC QJ01MA13
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
NCI_THESAURUS C795
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
LIVERTOX NBK547840
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID0041145
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
PRIMARY
DAILYMED
9F388J00UK
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
PRIMARY
CHEBI
9763
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
PRIMARY
CAS
147059-72-1
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
PRIMARY
MERCK INDEX
m11237
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
PRIMARY Merck Index
EVMPD
SUB11350MIG
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
PRIMARY
DRUG CENTRAL
2777
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
PRIMARY
INN
7370
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
PRIMARY
WIKIPEDIA
Trovafloxacin
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
PRIMARY
SMS_ID
100000089214
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
PRIMARY
MESH
C080163
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
PRIMARY
RXCUI
115552
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
PRIMARY RxNorm
LACTMED
Trovafloxacin
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
PRIMARY
ChEMBL
CHEMBL428
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
PRIMARY
NCI_THESAURUS
C66644
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
PRIMARY
FDA UNII
9F388J00UK
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
PRIMARY
DRUG BANK
DB00685
Created by admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
PRIMARY
Related Record Type Details
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
18 STRAINS LESS THE 8 ng/mL for many strains; mic range listed
MIC90
SALT/SOLVATE -> PARENT
TARGET ORGANISM->INHIBITOR
SALT/SOLVATE -> PARENT
EXCRETED UNCHANGED
FECAL
TRANSPORTER -> INHIBITOR
IC50
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
EXCRETED UNCHANGED
URINE
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
Related Record Type Details
ACTIVE MOIETY